Chicken hemoglobin peptide as well as preparation method and application thereof

The chicken hemoglobin peptide isolated after sonication and enzymatic lysis of alkaline proteases solved the problem of unutilized chicken blood resources, achieved xanthine oxidase inhibitory activity, achieved the effect comparable to traditional drugs, and enriched the types of uric acid-lowering drugs and Promote the high-value utilization of chicken by-products.

CN119040424APending Publication Date: 2024-11-29ZHONGKAI UNIV OF AGRI & ENG +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411451981.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-17
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Chicken blood resources are not fully utilized, resulting in the unutilization of nutritional value and application value. The existing chicken hemoglobin peptide products have not been reported, and the activity of traditional uric acid-lowering drugs is low.

Method used

After sonication and enzymatic lysis of alkaline protease, the chicken hemoglobin peptide with <1kDa was isolated by ultrafiltration, achieving the inhibitory activity of xanthine oxidase, achieving the effect comparable to that of the traditional uric acid-lowering drug allopurinol.

Benefits of technology

The efficient release of xanthine oxidase inhibitory activity of chicken hemoglobin peptides has been achieved, enriched the types of uric acid-lowering drug products, and promoted the high-value utilization of chicken by-products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040424A_ABST
    Figure CN119040424A_ABST
Patent Text Reader

Abstract

The invention discloses a chicken hemoglobin peptide as well as a preparation method and application thereof, and belongs to the technical field of biology. The preparation method of the chicken hemoglobin peptide comprises the following steps: performing ultrasonic treatment on chicken blood to obtain chicken hemoglobin, performing enzymolysis on the chicken hemoglobin through alkaline protease to obtain an enzymolysis product, and performing ultrafiltration separation on the enzymolysis product to obtain the chicken hemoglobin peptide. The molecular weight of the chicken hemoglobin peptide is less than 1kDa. The invention proves that the chicken hemoglobin peptide component obtained after alkaline protease enzymolysis can better release and play a role in inhibiting activity of xanthine oxidase, can achieve an effect almost equivalent to that of the traditional uric acid-reducing drug allopurinol, and provides a theoretical basis for enriching the variety of uric acid-reducing drug products. And meanwhile, the high-value utilization of chicken byproducts is promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to a chicken hemoglobin peptide and a preparation method and application thereof. Background Art

[0002] my country is a major broiler breeding and processing country, and its chicken production ranks second in the world. Chicken blood, as an important byproduct of the chicken slaughter process, is a valuable protein resource with rich nutrients. However, chicken blood resources have not been paid enough attention and the utilization rate is low. At present, most slaughterhouses often discharge chicken blood as waste, which not only increases the burden of environmental treatment, but also wastes precious chicken blood resources, resulting in its nutritional value and application value not being fully utilized.

[0003] As people's dietary standards improve, excessive purine intake from outside the body will be metabolized and accumulated in the body to produce uric acid, and gradually form hyperuricemia and gout symptoms. Studies have reported that inhibiting the activity of xanthine oxidase (XOD) in the human body can reduce uric acid production, thereby reducing blood uric acid concentration and relieving gout. Xanthine oxidase inhibitory peptides prepared by bioenzymatic hydrolysis using food protein sources as raw materials are becoming more and more popular because of their natural, safe, and non-toxic side effects. Most XOD inhibitory peptides come from marine fish proteins, such as bonito protein hydrolyzed by neutral protease. 50 The XOD IC value of ICRK identified from bluefin tuna hydrolysate was 14.88 mg / mL. 50 The value is 14.18mg / mL; there are also XOD inhibitory peptides derived from other proteins, such as walnut meal hydrolyzed by alkaline protease, with an XOD inhibition rate of 27.23% at a concentration of 20mg / mL. These hydrolyzates have lower activity than traditional uric acid-lowering drugs (allopurinol, IC 50 The value is 8.04 μg / mL). The most abundant protein in chicken blood is hemoglobin, which accounts for 12-18% of the total blood components. Therefore, using chicken hemoglobin as raw material and obtaining protein peptides with good xanthine oxidase inhibitory activity through biological enzymatic hydrolysis is of great significance to enrich the types of uric acid-lowering drug products.

[0004] In theory, the biological activity of peptides is determined by multiple factors such as protein structure, protease type and hydrolysis conditions. Therefore, the selection of appropriate protein substrates and proteases is crucial for enriching XOD inhibitory peptides. At present, chicken hemoglobin peptide products with xanthine oxidase inhibitory activity have not been reported. Summary of the invention

[0005] The purpose of the present invention is to provide a chicken hemoglobin peptide and a preparation method and application thereof to solve the problems existing in the above-mentioned prior art. The present invention confirms that the chicken hemoglobin peptide component obtained after alkaline protease hydrolysis can better release and exert the xanthine oxidase inhibitory activity, and can achieve an effect almost equivalent to that of the traditional uric acid-lowering drug allopurinol, providing a theoretical basis for enriching the types of uric acid-lowering drug products. At the same time, the present invention promotes the high-value utilization of chicken by-products.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides a method for preparing a chicken hemoglobin peptide having xanthine oxidase inhibitory activity, comprising the following steps:

[0008] Chicken blood is subjected to ultrasonic treatment to obtain chicken hemoglobin, the chicken hemoglobin is hydrolyzed by alkaline protease to obtain an enzymatic hydrolysis product, and the enzymatic hydrolysis product is separated by ultrafiltration to obtain the chicken hemoglobin peptide;

[0009] The molecular weight of the chicken hemoglobin peptide is less than 1 kDa.

[0010] Furthermore, the amount of alkaline protease added is 10-40 mg alkaline protease per 2 g chicken hemoglobin; the enzyme activity of the alkaline protease is 200 U / mg.

[0011] Furthermore, the amount of alkaline protease added is 20 mg of alkaline protease per 2 g of chicken hemoglobin.

[0012] Furthermore, the enzymatic hydrolysis temperature of the alkaline protease is 50°C.

[0013] Furthermore, the enzymatic hydrolysis time of the alkaline protease is 4 to 8 hours.

[0014] Furthermore, the enzymatic hydrolysis time of the alkaline protease is 6 hours.

[0015] Furthermore, before enzymatic hydrolysis, the pH of the chicken hemoglobin is 8.

[0016] Furthermore, before the ultrasonic treatment, the mixture is centrifuged at 4800 r / min and 4° C. for 15 min; the ultrasonic treatment time is 15-30 min.

[0017] The present invention also provides a chicken hemoglobin peptide having xanthine oxidase inhibitory activity obtained by the preparation method.

[0018] The present invention also provides application of the chicken hemoglobin peptide in preparing a medicine having uric acid-lowering activity.

[0019] The present invention discloses the following technical effects:

[0020] The present invention uses chicken hemoglobin as a raw material, and after one-step enzymatic hydrolysis and ultrafiltration, chicken hemoglobin peptides with good xanthine oxidase inhibitory activity can be obtained, and the preparation method and process are simple. The present invention proves that the chicken hemoglobin peptide component obtained after alkaline protease enzymatic hydrolysis can better release and exert the xanthine oxidase inhibitory activity, and can achieve an effect almost equivalent to that of the traditional uric acid-lowering drug allopurinol, providing a theoretical basis for enriching the types of uric acid-lowering drug products. At the same time, the present invention promotes the high-value utilization of chicken by-products. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 The xanthine oxidase inhibitory activity of different protease hydrolysates;

[0023] Figure 2 The xanthine oxidase inhibitory activity of alkaline protein hydrolysate at different times and enzyme addition amounts;

[0024] Figure 3 Xanthine oxidase inhibitory activity of alkaline protein hydrolysate and its ultrafiltration fractions. DETAILED DESCRIPTION

[0025] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0026] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0027] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0028] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0029] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0030] The papain, alkaline protease, compound protease and flavor protease in the embodiment of the present invention can be obtained by conventional commercial purchase. The papain, alkaline protease, compound protease and flavor protease selected in the present invention have enzymatic activities of 800U / mg, 200U / mg, 120U / mg and 20U / mg respectively.

[0031] Example

[0032] 1. Preparation of Chicken Hemoglobin

[0033] Fresh chicken blood was collected with sodium citrate as an anticoagulant at a total mass concentration of 3.2%. After the collection was completed, the chicken blood containing the anticoagulant was centrifuged at 4800r / min, 4°C for 15min, the supernatant was discarded, and the precipitate was taken. Subsequently, 3 times the volume of deionized water was added to the precipitate, and after ultrasonication for 15-30min, it was centrifuged at 4800r / min, 4°C for 15min, the supernatant was taken, and the crude chicken hemoglobin extract was obtained after freeze-drying.

[0034] 2. Preparation of chicken hemoglobin-derived xanthine oxidase inhibitory peptide

[0035] Chicken hemoglobin was hydrolyzed with papain, alkaline protease, compound protease and flavor protease to prepare chicken hemoglobin-derived xanthine oxidase inhibitory peptides.

[0036] (1) Papain hydrolysate

[0037] Take the above chicken hemoglobin as raw material (2g), add 100mL deionized water, and adjust the pH to 6.5 with 1M hydrochloric acid. Then, add different amounts of papain (10mg, 20mg and 40mg), hydrolyze at 50℃ for 4h, 6h and 8h, take out, inactivate the enzyme in 100℃ boiling water bath for 10min, adjust the pH to neutral, centrifuge at 8000r / min for 15min, and take the supernatant to obtain papain hydrolysates obtained by different enzyme addition amounts and different hydrolysis times.

[0038] (2) Alkaline protease hydrolysate

[0039] Take the above chicken hemoglobin as raw material (2g), add 100mL deionized water, and adjust the pH to 8 with 1M sodium hydroxide. Then, add different amounts of alkaline protease (10mg, 20mg and 40mg), hydrolyze at 50℃ for 4h, 6h and 8h, take out, inactivate the enzyme in 100℃ boiling water bath for 10min, adjust the pH to neutral, centrifuge at 8000r / min for 15min, and take the supernatant to obtain alkaline protease hydrolysates obtained by different enzyme addition amounts and different hydrolysis times.

[0040] (3) Composite protease hydrolysate

[0041] Take the above chicken hemoglobin as raw material (2g), add 100mL deionized water, and adjust the pH to 7.5 with 1M sodium hydroxide. Then, add different amounts of composite protease (10mg, 20mg and 40mg), hydrolyze at 50℃ for 4h, 6h and 8h, take out, inactivate the enzyme in 100℃ boiling water bath for 10min, adjust the pH to neutral, centrifuge at 8000r / min for 15min, and take the supernatant to obtain composite protease hydrolysates obtained by different enzyme addition amounts and different hydrolysis times.

[0042] (4) Flavor protease hydrolysate

[0043] Take the above chicken hemoglobin as raw material (2g), add 100mL deionized water, and adjust the pH to 6 with 1M hydrochloric acid. Then, add different amounts of flavor protease (10mg, 20mg and 40mg), respectively, and hydrolyze at 50℃ for 4h, 6h and 8h, take out, inactivate the enzyme in 100℃ boiling water bath for 10min, adjust the pH to neutral, centrifuge at 8000r / min for 15min, and take the supernatant to obtain flavor protease hydrolysates obtained with different enzyme addition amounts and different hydrolysis times.

[0044] The supernatants of the different protease hydrolysates of (1) to (4) were separated using 1 kDa and 3 kDa ultrafiltration tubes to obtain components of <1 kDa, 1-3 kDa, <3 kDa, and >3 kDa (first separated using a 3 kDa ultrafiltration tube to obtain components of 0-3 kDa and greater than 3 kDa, and then part of the 0-3 kDa component was passed through a 1 kDa ultrafiltration tube to obtain components of 0-1 kDa and 1-3 kDa), and freeze-dried to obtain different chicken hemoglobin-derived xanthine oxidase inhibitory peptides.

[0045] 3. Yield of chicken hemoglobin-derived xanthine oxidase inhibitory peptide

[0046] Determination method: The substrate is 2g chicken hemoglobin, and the enzymatic hydrolysates with different protease addition amounts of 20mg and reaction time of 6h are selected. After freeze-drying, the mass of the freeze-dried product obtained is divided by the mass of the raw material input for enzymatic hydrolysis (2g) to calculate the yield. The final yield value is the average value obtained after two experiments.

[0047] The measurement results are shown in Table 1.

[0048] Table 1 Yield of xanthine oxidase inhibitory peptides derived from chicken hemoglobin

[0049] Protease Enzyme addition amount (mg) Reaction time (h) Yield Flavor protease 20 6 13.05% Alkaline protease 20 6 29.25% Papain 20 6 14.5% Compound protease 20 6 10.85%

[0050] 4. Xanthine oxidase inhibitory activity assay

[0051] Determination method: Take 50 μL of the sample to be tested or phosphate buffer (0.05M, pH = 7.4) and add it to a 96-well plate, then add 50 μL of 0.05U / mL xanthine oxidase solution, and incubate the mixture at 37°C for 15 minutes. Subsequently, add 150 μL of 0.40mM xanthine solution, incubate at 37°C for another 30 minutes, and measure the absorbance at 290nm. Calculate the inhibition rate of the sample to be tested on xanthine oxidase, and the inhibition rate calculation formula is as follows:

[0052]

[0053] Among them, A1 represents the absorbance of the sample solution with enzyme added; A2 represents the absorbance of the sample solution without enzyme added; A3 represents the absorbance of the blank group with buffer replacing the sample solution; A4 represents the absorbance of the blank group without enzyme added.

[0054] The enzyme addition amount of different proteases was 20 mg, and the enzymatic reaction time was 6 h. The supernatant of the enzymatic hydrolysate was tested. The results are as follows: Figure 1 As shown. Figure 1It can be seen that when the amount of enzyme added and the enzymolysis reaction time are the same, the enzymolysis product of alkaline protease has the highest inhibitory activity on xanthine oxidase. Therefore, the enzymolysis product of alkaline protease was selected to further analyze the effect of the enzymolysis products of different enzyme addition amounts and different enzymolysis reaction times on the inhibitory activity of xanthine oxidase.

[0055] The supernatants of the enzymatic products obtained at different alkaline protease addition amounts (10 mg, 20 mg and 40 mg) and different enzymatic reaction times (enzymatic hydrolysis 4 h, 6 h and 8 h) were selected for detection. The results are as follows: Figure 2 shown. Figure 2 In the table, 0.5%, 1% and 2% correspond to 10mg, 20mg and 40mg of enzyme addition respectively, and the percentage means the percentage of enzyme addition to the substrate chicken hemoglobin mass. Figure 2 It can be seen that when the addition amount of alkaline protease is 20 mg and the enzymatic reaction time is 6 h, the enzymatic hydrolysis product obtained has the highest inhibitory activity on xanthine oxidase.

[0056] In order to explore the difference in the inhibitory activity of different fractions on xanthine oxidase, the enzymatic hydrolysis product with an alkaline protease addition of 20 mg and an enzymatic hydrolysis reaction time of 6 h, as well as the different components obtained after the product was separated by 1 kDa and 3 kDa ultrafiltration tubes were selected as the test samples. The concentrations of the test samples were adjusted to 10 mg / mL and 20 mg / mL, respectively, and the inhibitory activity was determined. The results are shown in Figure 2. Figure 3 As shown. Figure 3 It can be seen that the activity of the components before ultrafiltration was 33.30±6.79 (10 mg / mL) and 62.09±9.59 (20 mg / mL); after ultrafiltration, the activity of the components <1kDa was 35.75±3.45 (10 mg / mL) and 62.09±4.40 (20 mg / mL). It can be seen that the <1kDa component is slightly better than the crude extract, and the relative deviation is smaller. Therefore, the <1kDa component obtained after ultrafiltration has the best inhibitory activity on xanthine oxidase, and can achieve an effect almost equivalent to that of the traditional uric acid-lowering drug allopurinol.

[0057] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A method for preparing a chicken hemoglobin peptide having xanthine oxidase inhibitory activity, characterized in that: The following steps are involved: Chicken blood is subjected to ultrasonic treatment to obtain chicken hemoglobin, the chicken hemoglobin is hydrolyzed by alkaline protease to obtain an enzymatic hydrolysis product, and the enzymatic hydrolysis product is separated by ultrafiltration to obtain the chicken hemoglobin peptide; The molecular weight of the chicken hemoglobin peptide is less than 1 kDa.

2. The preparation method according to claim 1, characterized in that: The added amount of the alkaline protease is 10-40 mg of alkaline protease per 2 g of chicken hemoglobin; the enzyme activity of the alkaline protease is 200 U / mg.

3. The preparation method according to claim 2, characterized in that: The added amount of the alkaline protease is 20 mg of alkaline protease per 2 g of chicken hemoglobin.

4. The preparation method according to claim 1, characterized in that: The enzymatic hydrolysis temperature of the alkaline protease is 50°C.

5. The preparation method according to claim 1, characterized in that: The enzymatic hydrolysis time of the alkaline protease is 4 to 8 hours.

6. The preparation method according to claim 5, characterized in that: The enzymatic hydrolysis time of the alkaline protease is 6 hours.

7. The preparation method according to claim 1, characterized in that: Before enzymatic hydrolysis, the pH of the chicken hemoglobin is 8.

8. The preparation method according to claim 1, characterized in that: Before the ultrasonic treatment, the method further includes centrifuging at 4800 r / min and 4° C. for 15 min; the ultrasonic treatment time is 15-30 min.

9. A chicken hemoglobin peptide having xanthine oxidase inhibitory activity obtained by the preparation method according to any one of claims 1 to 8.

10. Use of the chicken hemoglobin peptide according to claim 9 in the preparation of a drug having uric acid-lowering activity.

Citation Information

Patent Citations

  • Cod polypeptide with xanthine oxidase inhibitory activity

    CN113005166A

  • Preparation method and application of xanthine oxidase inhibitory peptide

    CN114044802A

  • Application of oyster polypeptide in preparation of drugs for inhibiting xanthine oxidase

    CN115845023A

  • Duck blood globulin peptide with uric acid reducing activity and preparation method of duck blood globulin peptide

    CN117186177A

  • Preparation method of xanthine oxidase inhibitory peptide and application of xanthine oxidase inhibitory peptide in preparation of uric acid reducing product

    CN118146302A